Spinal Arthritis Market Worthwhile As 'Add-On' To Existing Therapies
By Randall Osborne
Monday, March 15, 2004
Industry pundits have been chanting about "consolidation" for years, using each new buyout as a way of proving their forecast - which, let's face it, is pretty much a fail-safe prediction.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.